# Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia

> **NCT03663829** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 2052 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **OTHER:** Non-Interventional
- **OTHER:** Non-Interventional

## Key facts

- **NCT ID:** NCT03663829
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-04
- **Primary completion:** 2019-03-05
- **Final completion:** 2019-12-18
- **Target enrollment:** 2052 (ACTUAL)
- **Last updated:** 2022-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03663829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03663829, "Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03663829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*